Kyverna Therapeutics/$KYTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
$KYTX
Sector
Primary listing
Employees
129
Headquarters
Website
KYTX Metrics
BasicAdvanced
$287M
-
-$3.67
-
-
Price and volume
Market cap
$287M
52-week high
$7.73
52-week low
$1.78
Average daily volume
664K
Financial strength
Current ratio
5.387
Quick ratio
5.32
Long term debt to equity
1.27
Total debt to equity
3.21
Interest coverage (TTM)
-1,769.37%
Profitability
EBITDA (TTM)
-170.441
Management effectiveness
Valuation
Price to book
1.56
Price to tangible book (TTM)
1.56
Price to free cash flow (TTM)
-2.015
Free cash flow yield (TTM)
-49.64%
Free cash flow per share (TTM)
-3.291
Growth
What the Analysts think about KYTX
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
KYTX Financial Performance
Revenues and expenses
KYTX Earnings Performance
Company profitability
KYTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kyverna Therapeutics stock?
Kyverna Therapeutics (KYTX) has a market cap of $287M as of October 12, 2025.
What is the P/E ratio for Kyverna Therapeutics stock?
The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of October 12, 2025.
Does Kyverna Therapeutics stock pay dividends?
No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Kyverna Therapeutics dividend payment date?
Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Kyverna Therapeutics?
Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.